What is ARTBIO?
Headquartered in Cambridge, Massachusetts, ARTBIO is fundamentally transforming the landscape of cancer treatment through the engineering of alpha radioligand therapies (ART). Unlike traditional modalities, the company's approach focuses on creating a comprehensive ecosystem that maximizes the therapeutic potential of alpha-emitting isotopes. By integrating advanced scientific research with a scalable operational framework, ARTBIO is addressing critical gaps in oncology, aiming to deliver highly targeted, effective treatments that minimize systemic toxicity while maximizing patient outcomes. The company's market position is bolstered by its ability to attract top-tier institutional investors who specialize in disruptive life sciences and healthcare innovation.
How much funding has ARTBIO raised?
ARTBIO has raised a total of $245M across 3 funding rounds:
Angel/Seed
$23M
Series A
$90M
Series B
$132M
Angel/Seed (2023): $23M with participation from F-Prime Capital Partners
Series A (2023): $90M led by Third Rock Ventures, Omega Fund Management, and F-Prime Capital Partners
Series B (2025): $132M supported by Omega Fund Management, F-Prime Capital, Third Rock Ventures, Alexandria, Qatar Investment Authority, B Capital Group, and Sofinnova Partners
Key Investors in ARTBIO
F-Prime Capital
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies. F-Prime Capital is located in Massachusetts.
Third Rock Ventures
Founded in 2007, Third Rock Ventures is a healthcare venture firm focused on disruptive areas of science and medicine to discover, launch and build companies that make a dramatic difference in people's lives.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability, acting as a hands-on company builder across the entire value chain.
What's next for ARTBIO?
With the successful closure of this major strategic investment, ARTBIO is entering a critical phase of clinical expansion and infrastructure development. The company is expected to utilize these resources to advance its lead candidates through rigorous clinical trials while simultaneously scaling its manufacturing and supply chain capabilities to support future commercialization. As the firm continues to build out its therapeutic ecosystem, the focus will remain on translating complex scientific breakthroughs into viable, life-saving medical solutions. This strategic growth phase positions ARTBIO to potentially disrupt the broader radiopharmaceutical market, setting a new benchmark for precision oncology and long-term value creation for stakeholders.
See full ARTBIO company page
